home > events calendar > more about event

BioProcess International Conference & Exhibition (BPI)

25-28 September 2017
Hynes Convention Center, Boston, Massachusetts, USA

BioProcess International Conference & Exhibition (BPI) is the largest bioprocessing event bringing you the science, technologies and partners needed to accelerate promising biologics towards commercial success.  Join 1800+ global bioprocessing professionals at this year’s meeting, held September 25-28, 2017 at the Hynes Convention Center in Boston.  The 2017 scientific agenda covers important industry updates and new data across entire bioprocessing spectrum, from early stage process development through late stage commercial manufacturing.  We are pleased to announce the confirmation of our first two keynote speakers:

  • Improving Global Access to Biotherapeutics through Molecule, Process and Manufacturing Design: Dean K. Pettit, Ph.D., CSO and Founding Partner, Just Biotherapeutics
  • Tools for Mapping and Repairing Disease States: Can We Make Therapeutic Invention into a Mature Design Science?: Ed Boyden, Ph.D., Associate Professor, Media Lab and McGovern Institute, MIT

Readers of European Biopharmaceutical Review can receive a 10% registration discount off current rates by registering with VIP code EBR10 online at (new registrations only).  If you have any questions about participating at this year’s meeting, please contact Event Marketing Manager Howie Choi at

Print this page
Send to a friend
Industry Events

Vaccine Manufacturing

23-25 April 2018, RAI, Amsterdam

Changing the shape of vaccine development, manufacturing and delivery.
More info >>

Banner of T3_events_97 on Samedan Banner of ChinaBio_Events_102 on Samedan

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach


In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

News and Press Releases

Life Sciences Regulatory Association Announces Speaker

March 8, 2018 (East Hartford, Conn.) – RWS Life Sciences Managing Director, Sheena Dempsey, will present “Understanding Language Compliance for Global Markets” to the Chicago Chapter of the Regulatory Affairs Professionals Society (RAPS), on March 21, at 5:30 PM (CDT), at AbbVie, Inc., in North Chicago.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement